Literature DB >> 9137129

Decreased left frontal lobe N-acetylaspartate in schizophrenia.

R F Deicken1, L Zhou, F Corwin, S Vinogradov, M W Weiner.   

Abstract

OBJECTIVE: The authors measured N-acetylaspartate (a putative neuronal marker), using in vivo proton magnetic resonance spectroscopic imaging (1H-MRSI), in the frontal lobes of schizophrenic patients and normal subjects.
METHOD: Frontal lobe 1H-MRSI was performed bilaterally on 24 medicated schizophrenic patients and 15 healthy comparison subjects. Levels of N-acetylaspartate, creatine, and choline were determined.
RESULTS: Relative to the comparison group, the patients with schizophrenia demonstrated significantly lower levels of N-acetylaspartate in the left frontal lobe. There was no association between level of N-acetylaspartate and duration of illness or medication dosage. No differences between groups or lateralized asymmetries in choline or creatine were noted.
CONCLUSIONS: This preliminary study provides support for decreased N-acetylaspartate in the left frontal lobe in schizophrenia and neuronal dysfunction in this brain region.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9137129     DOI: 10.1176/ajp.154.5.688

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  9 in total

1.  Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia.

Authors:  Frank A Middleton; Karoly Mirnics; Joseph N Pierri; David A Lewis; Pat Levitt
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

Review 2.  Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

Authors:  Robert E McCullumsmith; John Hammond; Adam Funk; James H Meador-Woodruff
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

Review 3.  Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis.

Authors:  Nina Vanessa Kraguljac; Meredith Reid; David White; Rebecca Jones; Jan den Hollander; Deborah Lowman; Adrienne Carol Lahti
Journal:  Psychiatry Res       Date:  2012-09-13       Impact factor: 3.222

4.  Proton magnetic resonance spectroscopy (H-MRS) in chronic schizophrenia. A single-voxel study in three regions involved in a pathogenetic theory.

Authors:  F Granata; G Pandolfo; S Vinci; C Alafaci; N Settineri; R Morabito; A Pitrone; M Longo
Journal:  Neuroradiol J       Date:  2013-07-16

5.  Proton magnetic resonance spectroscopy and thought disorder in childhood schizophrenia.

Authors:  Ronald R Seese; Joseph O'Neill; Matthew Hudkins; Prabha Siddarth; Jennifer Levitt; Ben Tseng; Keng Nei Wu; Rochelle Caplan
Journal:  Schizophr Res       Date:  2011-08-27       Impact factor: 4.939

Review 6.  Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses.

Authors:  Tomás R Guilarte; Mark Opler; Mikhail Pletnikov
Journal:  Neurotoxicology       Date:  2011-12-09       Impact factor: 4.294

Review 7.  [Magnetic resonance spectroscopy in schizophrenia. Possibilities and limitations].

Authors:  T Wobrock; H Scherk; P Falkai
Journal:  Radiologe       Date:  2005-02       Impact factor: 0.635

Review 8.  T2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia.

Authors:  Bethany K Bracken; Elizabeth D Rouse; Perry F Renshaw; David P Olson
Journal:  Psychiatry Res       Date:  2013-06-12       Impact factor: 3.222

9.  Metabolite differences in the medial prefrontal cortex in schizophrenia patients with and without persistent auditory verbal hallucinations: a 1H MRS study.

Authors:  Qianjin Wang; Honghong Ren; Chunwang Li; Zongchang Li; Jinguang Li; Hong Li; Lulin Dai; Min Dong; Jun Zhou; Jingqi He; Joseph O'Neill; Yanhui Liao; Ying He; Tieqiao Liu; Xiaogang Chen; Jinsong Tang
Journal:  Transl Psychiatry       Date:  2022-03-23       Impact factor: 6.222

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.